Verona Historical Cash Flow
| VRNA Stock | USD 63.00 1.51 2.34% |
Analysis of Verona Pharma cash flow over time is an excellent tool to project Verona Pharma PLC future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Cash of 134.4 M or Other Cashflows From Financing Activities of 87.2 M as it is a great indicator of Verona Pharma ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Verona Pharma PLC latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Verona Pharma PLC is a good buy for the upcoming year.
Verona |
About Verona Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Verona balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Verona's non-liquid assets can be easily converted into cash.
Verona Pharma Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most accounts from Verona Pharma's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Verona Pharma PLC current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verona Pharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At present, Verona Pharma's Change In Cash is projected to increase significantly based on the last few years of reporting. The current year's Other Cashflows From Financing Activities is expected to grow to about 87.2 M, whereas Free Cash Flow is projected to grow to (116.1 M).
Verona Pharma cash flow statement Correlations
Click cells to compare fundamentals
Verona Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Verona Pharma cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 157.6M | (39.6M) | 79.4M | 43.9M | 128.0M | 134.4M | |
| Free Cash Flow | (45.2M) | (33.3M) | (59.9M) | (50.2M) | (122.2M) | (116.1M) | |
| Change In Working Capital | (2.1M) | 13.4M | (10.7M) | (14.0M) | (5.7M) | (5.5M) | |
| Other Cashflows From Financing Activities | (12.8M) | (6.9M) | (14.0M) | (2.7M) | 83.0M | 87.2M | |
| Other Non Cash Items | 18K | 239K | 4.8M | (332.4K) | 7.6M | 8.0M | |
| Capital Expenditures | 82K | 12K | 29K | 4.07 | 580K | 609K | |
| Total Cash From Operating Activities | (45.1M) | (33.3M) | (59.9M) | (50.2M) | (122.2M) | (116.1M) | |
| Net Income | (65.1M) | (55.6M) | (68.7M) | (54.6M) | (173.4M) | (164.7M) | |
| Total Cash From Financing Activities | 192.3M | (6.1M) | 140.8M | 92.9M | 250.8M | 263.3M | |
| End Period Cash Flow | 188.0M | 148.4M | 227.8M | 271.8M | 399.8M | 419.7M | |
| Stock Based Compensation | 22.2M | 25.4M | 14.1M | 19.0M | 41.2M | 43.3M | |
| Begin Period Cash Flow | 30.4M | 188.0M | 148.4M | 227.8M | 271.8M | 285.4M | |
| Depreciation | 623K | 629K | 636K | 116K | 2.4M | 2.5M | |
| Total Cashflows From Investing Activities | 47.3M | 9.7M | (12K) | (29K) | (33.4K) | (31.7K) | |
| Change To Account Receivables | 774.0K | (6.9M) | 4.0M | (1.1M) | (31.5M) | (29.9M) | |
| Change To Operating Activities | 1.4M | (1.5M) | 10.4M | (7.7M) | (8.8M) | (8.4M) | |
| Other Cashflows From Investing Activities | 7.2M | (12K) | (29K) | (580K) | (667K) | (633.7K) | |
| Change To Netincome | 1.5M | 21.6M | 8.1M | 18.9M | 21.7M | 22.8M | |
| Change To Liabilities | (1.7M) | (1.4M) | 9.9M | (7.1M) | (6.4M) | (6.1M) | |
| Change To Inventory | (774.0K) | 6.9M | (4.0M) | 1.0 | (8.2M) | (7.8M) | |
| Investments | 9.7M | (12K) | (29K) | 0.0 | (580K) | (609K) | |
| Issuance Of Capital Stock | 200.2M | 733K | 149.8M | 56.9M | 97.5M | 79.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verona Pharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verona Pharma. If investors know Verona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verona Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Verona Pharma PLC is measured differently than its book value, which is the value of Verona that is recorded on the company's balance sheet. Investors also form their own opinion of Verona Pharma's value that differs from its market value or its book value, called intrinsic value, which is Verona Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verona Pharma's market value can be influenced by many factors that don't directly affect Verona Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verona Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verona Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verona Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.